Business · 03/02/2003

FDA Releases Draft Guidance for Labeling Noncontraceptive Estrogen Drug Products

The Food and Drug Administration (FDA) has made available a draft guidance document to help healthcare providers and patients understand the labeling requirements for noncontraceptive estrogen drug products used to treat vasomotor symptoms and vulvar and vaginal atrophy symptoms.